Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
par Burstein, Harold J;Piccart-Gebhart, Martine 
;Perez, Edith A;Hortobagyi, Gabriel N.;Wolmark, Norman;Albain, Kathy S;Norton, Larry;Winer, Eric P;Hudis, Clifford
Référence Journal of clinical oncology, 30, 18, page (2179-2182)
Publication Publié, 2012-06
;Perez, Edith A;Hortobagyi, Gabriel N.;Wolmark, Norman;Albain, Kathy S;Norton, Larry;Winer, Eric P;Hudis, CliffordRéférence Journal of clinical oncology, 30, 18, page (2179-2182)
Publication Publié, 2012-06
Article révisé par les pairs
| Titre: |
|
| Auteur: | Burstein, Harold J; Piccart-Gebhart, Martine; Perez, Edith A; Hortobagyi, Gabriel N.; Wolmark, Norman; Albain, Kathy S; Norton, Larry; Winer, Eric P; Hudis, Clifford |
| Informations sur la publication: | Journal of clinical oncology, 30, 18, page (2179-2182) |
| Statut de publication: | Publié, 2012-06 |
| Sujet CREF: | Cancérologie |
| MeSH keywords: | Anthracyclines -- administration & dosage -- adverse effects |
| Antibodies, Monoclonal, Humanized -- administration & dosage | |
| Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
| Breast Neoplasms -- drug therapy -- metabolism | |
| Chemotherapy, Adjuvant | |
| Heart Failure -- chemically induced | |
| Humans | |
| Molecular Targeted Therapy | |
| Receptor, erbB-2 -- immunology -- metabolism | |
| Note générale: | Journal Article |
| Research Support, Non-U.S. Gov't | |
| SCOPUS: no.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0732-183X |
| info:doi/10.1200/JCO.2012.42.0695 | |
| info:pii/JCO.2012.42.0695 | |
| info:scp/84864018416 | |
| info:pmid/22614986 |
